Wuxi to Help Develop, Manufacture ADC Candidate in China

- Last updated on GMT

Wuxi to Help Develop, Manufacture ADC Candidate in China

Related tags: Pre-clinical development

Ambrx and Zhejiang Medicine have selected Wuxi to accelerate the development of a potential ADC (antibody drug conjugate) targeting Her2-positive breast cancer.

In this deal, WuXi will provide contract services to Ambrx and Zhejiang from process development, manufacturing clinical drug including conjugating antibody with toxin, preclinical studies and potentially perform clinical trials in China​,” Wuxi spokesman Aaron Shi told us.

San Diego-based biopharma company Ambrx sought the partnership with Zhejiang and Wuxi to gain access to the Chinese market for ARX788, which is the company’s most advanced ADC for breast and gastric cancer indications.

Zhejiang will bear the development costs and will gain commercial rights in China, while Ambrx keeps its commercial rights outside of China and will receive royalties on sales of the ADC in China.

Ambrx and Zhejiang will “leverage WuXi's capabilities to bring innovative antibody-ADC drug to China much faster than they can do by themselves​,” Shi said.

The partnership shows further progress the company is making in the development of biologics, which it said would be expected in comments from its latest earnings call​.

Wuxi is the only company in China to have this integrated biologics drug discovery, development and manufacturing capabilities that meet global quality standard​,” Shi added.

Last October, the company opened a biologics manufacturing facility​ in Wuxi, China, and which the company claims is the country’s first site to comply with US and EU GMP (good manufacturing practice) standards.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us


View more